Skip to Content

Silence Therapeutics PLC SLNCF Stock Quote

| Rating as of


Morningstar‘s Stock Analysis SLNCF

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics SLNCF

Company Profile SLNCF

Business Description

Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany.

72 Hammersmith Road
London, W14 8TH, United Kingdom
T +44 2034576900
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 105